Clinical Trials in Portugal — Country Dashboard | 875 EU Studies

Filter these 875 trials by condition, phase, sponsor and more.

Open in Search →

875 Registered trials

326 Recruiting

504 Completed trials

277 Sponsors active

158 Research sites

Phase III

Phase II

Phase III: 529 Phase II/III: 47 Phase II: 129 Phase I/II: 16 Phase III/IV: 11 Phase IV: 21 Phase I: 13 Phase I (Other): 30 Phase I (FiH): 13 Other: 66

Oversight events in trials active here:

52 serious breaches 245 temporary halts 26 urgent safety measures 35 unexpected events 47 corrective measures across 143 trials

View oversight register →

Top conditions

Non-small cell lung cancer 31 Pulmonary arterial hypertension 12 Multiple sclerosis 12 Crohn's disease 11 HER2 positive breast cancer 10 Systemic lupus erythematosus 9 Breast cancer 9 Hormone receptor positive HER2 negative breast cancer 9 Non-small cell lung cancer metastatic 7 Dermatitis atopic 7 Squamous cell carcinoma of head and neck 6 Dementia Alzheimer's type 6

Top sponsors

Novartis Pharma AG 44 Merck Sharp & Dohme LLC 42 F. Hoffmann-La Roche AG 39 Janssen - Cilag International 39 AbbVie Deutschland GmbH & Co. KG 38 Amgen Inc. 29 AstraZeneca AB 29 Sanofi-Aventis Recherche & Developpement 25 Boehringer Ingelheim International GmbH 23 Novo Nordisk A/S 22 Boehringer Ingelheim Espana S.A. 20 Bluepharma Industria Farmaceutica S.A. 17

Cities with most trials

All 49 cities →

All trials — page 29

875 total

Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN… Ended

2023-508812-45-00 Phase II/III Idiopathic Generalized Epilepsy with Generalized Tonic-cloni… Biohaven Therapeutics Ltd.
Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects. Ended

2024-516854-23-00 Phase I No medical condition. Laboratorios Leon Farma S.A.
Effects of Digoxin in Modern Heart Failure Treatment Ended

2024-513448-26-00 Phase IV Heart Failure Unidade Local De Saude De Sao Jose E.P.E.
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions. Ended

2024-515947-49-00 No medical condition. Bluepharma Industria Farmaceutica S.A.
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511360-87-00 Phase III hidradenitis suppurativa (HS) MoonLake Immunotherapeutics AG
Bioequivalence of Linagliptin 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended

2024-516400-42-00 No medical condition. Tecnimede-Sociedade Tecnico-Medicinal S.A.
Pharmacokinetics and the Effect of Food on the Pharmacokinetics of TW102 in Healthy Subjects. Ended

2024-510936-31-00 Phase I (Other) No medical condition. Treeway TW001AD B.V.
A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease Ended

2023-506805-20-01 Phase III Neurodegenerative Diseases Alector LLC
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended

2024-511647-25-00 No medical condition. Bluepharma Industria Farmaceutica S.A.
A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended

2023-505797-15-00 Phase III SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Cytokinetics Inc.
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-512908-19-00 No medical condition. Bluepharma Industria Farmaceutica S.A.
Exploratory Bioavailability of Three Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed Conditions (Hig… Ended

2024-514298-23-00 Phase I (Other) No medical condicion. Institut De Recherches Internationales Servier IRIS
Safety Study to Compare the Gastrointestinal Tolerability of Oral Tegomil Fumarate and Dimethyl Fumarate (Tecfidera®) in Healthy Volunteers. Ended

2023-508439-30-00 Phase I (Other) Multiple Sclerosis Neuraxpharm Pharmaceuticals S.L.
A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni… Ended

2023-505755-40-00 Phase II Chronic kidney disease Bayer AG
Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL… Ended

2024-513753-75-00 No medical condition. Bial Portela & Ca S.A.
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-514448-10-00 No medical condition. Bluepharma Industria Farmaceutica S.A.
European randomised clinical trial on mPOX Infection (EPOXI) Ended

2022-501979-10-00 Phase IV Monkeypox University Medical Center Utrecht
Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended

2024-513752-15-00 No medical condition. Bial Portela & Ca S.A.
Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions. Ended

2024-513751-32-00 No medical condition. Bial Portela & Ca S.A.
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr… Ended

2023-506185-31-00 Phase II/III Idiopathic pulmonary fibrosis (IPF) Pliant Therapeutics Inc.
Bioequivalence of Vortioxetine 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended

2023-509422-21-00 No medical condition. Laboratorios Cinfa S.A.
Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjects Ended

2023-504901-34-00 No medical condition. Synthon Chile LTDA.
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions. Ended

2024-512910-16-00 No medical condition. Bluepharma Industria Farmaceutica S.A.
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction Ended

2023-506210-40-00 Phase III Heart Failure due to Systemic Left Ventricular Systolic Dysf… Merck Sharp & Dohme LLC

Showing 673–696 of 875 trials

← All countries